A Bayesian phase I/II design for cancer clinical trials combining an immunotherapeutic agent with a chemotherapeutic agent-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Bayesian phase I/II design for cancer clinical trials combining an immunotherapeutic agent with a chemotherapeutic agent

Published:2021-06-14 Issue:5 Volume:70 Page:1210-1229
ISSN:0035-9254
Container-title:Journal of the Royal Statistical Society: Series C (Applied Statistics)
language:en
Short-container-title:J R Stat Soc Series C

Author:

Guo Beibei¹^ORCID,Garrett‐Mayer Elizabeth²,Liu Suyu³^ORCID

Affiliation:

1. Department of Experimental Statistics Louisiana State University Baton Rouge LA70803USA

2. Center for Research and Analytics (CENTRA) American Society of Clinical Oncology Alexandria VA22314USA

3. Department of Biostatistics The University of Texas MD Anderson Cancer Center Houston Texas77030USA

Publisher

Wiley

Subject

Statistics, Probability and Uncertainty,Statistics and Probability

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/rssc.12508

Reference38 articles.

1. A Hierarchical Bayesian Design for Phase I Trials of Novel Combinations of Cancer Therapeutic Agents

2. A Bayesian dose finding design for oncology clinical trials of combinational biological agents

3. An Adaptive Dose-Finding Design Based on Both Safety and Immunologic Responses in Cancer Clinical Trials

4. Cancer Immunotherapy

5. Combination immunotherapy approaches

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adaptive phase I–II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies;Clinical Trials;2024-01-11

2. Challenges in the combination of radiotherapy and immunotherapy for breast cancer;Expert Review of Anticancer Therapy;2023-04-03

3. A Bayesian phase I/II biomarker-based design for identifying subgroup-specific optimal dose for immunotherapy;Statistical Methods in Medical Research;2022-02-22

4. BIPSE: A biomarker‐based phase I/II design for immunotherapy trials with progression‐free survival endpoint;Statistics in Medicine;2021-11-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3